{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Replimune Group, Inc.
Is Replimune Group, Inc. technically bullish or bearish?
As of June 17, 2025, the technical trend is neutral with mixed signals: while the MACD shows mild bullishness, Bollinger Bands and daily moving averages indicate bearishness, resulting in an overall lack of clear direction.
Who are in the management team of Replimune Group, Inc.?
As of March 2022, the management team of Replimune Group, Inc. includes Mr. Dieter Weinand (Independent Chairman), Dr. Robert Coffin (President and Chief R&D Officer), and Mr. Philip Astley-Sparke (CEO). The Board also features independent directors such as Dr. Kapil Dhingra and Dr. Hyam Levitsky.
What does Replimune Group, Inc. do?
Replimune Group, Inc. is a clinical-stage biotechnology company focused on oncolytic immunotherapy for cancer treatment, with a market cap of approximately $732.71 million and a recent net profit loss of $74 million. The company has no dividend yield and negative return on equity.
How big is Replimune Group, Inc.?
As of Jun 18, Replimune Group, Inc. has a market capitalization of 732.71 million and reported net sales of 0.00 million with a net profit of -247.29 million over the latest four quarters. Shareholder's funds are 415.84 million, and total assets amount to 551.33 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
